Related Experiment Videos
Hashimoto's encephalopathy: epidemiologic data and pathogenetic considerations
Franco Ferracci1, Gianni Bertiato, Giuseppe Moretto
1Division of Neurology, Ospedale "S. Martino", Viale Europa 32100 Belluno, Italy. franco.ferracii@ulss.bellumo.it
Journal of the Neurological Sciences
|January 7, 2004
Summary
Hashimoto's encephalopathy (HE) diagnosis requires more than high anti-thyroid antibodies. Intrathecal synthesis of these antibodies in cerebrospinal fluid (CSF) is a key diagnostic marker for HE, independent of thyroid status.
Area of Science:
- Neurology
- Immunology
- Endocrinology
Background:
- Hashimoto's encephalopathy (HE) is a rare neurological condition associated with Hashimoto's thyroiditis (HT).
- Diagnosis is often suspected based on elevated serum anti-thyroid antibodies.
- Previous research indicated intrathecal synthesis of anti-thyroid antibodies in HE patients.
Purpose of the Study:
- To estimate the prevalence of HE.
- To verify the association between HE and HT.
- To investigate the pathogenetic role of anti-thyroid antibodies in HE.
Main Methods:
- A 34-month prospective study involving patients with unexplained encephalopathy or myelopathy.
- Measurement of serum and cerebrospinal fluid (CSF) anti-thyroid antibodies.
- Correlation of antibody levels with clinical presentation and treatment response.
Main Results:
- The estimated prevalence of HE was 2.1 per 100,000 people.
- Only six of the nine diagnosed HE patients also had HT.
- CSF anti-thyroid antibody levels did not correlate with clinical status or treatment, and symptom course was independent of therapy.
Conclusions:
- High serum anti-thyroid antibodies alone are insufficient for diagnosing HE.
- Intrathecal synthesis of autoantibodies in CSF is a distinctive marker for HE.
- The diagnosis of HE should rely on CSF findings, irrespective of the thyroid gland's clinical status.